Mustef (Dimethyl Fumarate)

Dimethyl fumarate, the active ingredient in Mustef, is an immunomodulator presented as an oral formulation for oral use. It is indicated for the management of relapsing forms of multiple sclerosis and for moderate to severe plaque psoriasis in adult patients.

GNH USA supplies Mustef as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Customers benefit from reliable supply chains and responsive technical support.

Dimethyl fumarate is used in diseases mediated by immune dysregulation, particularly within the multiple sclerosis and psoriasis therapeutic areas.

- Multiple sclerosis: reduces relapse frequency and slows disease progression. - Relapsing‑remitting multiple sclerosis: decreases the number of clinical attacks. - Plaque psoriasis: improves skin lesions and lowers disease severity.

Common Side Effects: - Flushing: transient warmth and redness, often on the face. - Gastrointestinal upset: nausea, abdominal pain, or diarrhea. - Lymphopenia: mild reduction in white blood cell count. - Headache: mild to moderate intensity. - Pruritus: itching without rash. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Severe lymphopenia: marked decrease in lymphocytes increasing infection risk. - Hepatic injury: elevated liver enzymes or hepatitis. - Anaphylaxis: acute allergic reaction with airway compromise. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Dimethyl fumarate requires careful monitoring and patient education to minimize risks. - Monitor lymphocyte counts: perform baseline and periodic blood tests. - Assess liver function: check hepatic enzymes before initiation and during therapy. - Avoid use in active infections: defer treatment until infection resolves. - Use caution in renal impairment: adjust monitoring frequency. - Counsel on flushing: advise taking with food and avoiding alcohol. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Dimethyl fumarate may interact with other agents that affect immune function or metabolism.

Major Interactions (Avoid): - Concomitant immunosuppressants (e.g., azathioprine, cyclophosphamide): increased risk of severe immunosuppression. - Live vaccines: may lead to uncontrolled infection. - Strong CYP inducers (e.g., rifampin): may reduce drug exposure.

Moderate Interactions (Monitor Closely): - Antacids: may alter gastrointestinal absorption; monitor efficacy. - NSAIDs: increased risk of gastrointestinal irritation. - Non‑live vaccines: possible reduced immunogenic response; assess antibody titers. - Warfarin: potential alteration of INR; monitor coagulation parameters. - Alcohol: may exacerbate flushing and gastrointestinal side effects.